New York, NY—February 14, 2019 Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the first $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”).
Glycotest, Inc. Receives $3 Million First Tranche of $10 Million Series A Financing
Related News
Other posts that you should not miss.
Glycotest, Inc. Receives $3 Million First Tranche of $10 Million Series A Financing | Glycotest Diagnostics